Nature Communications (Nov 2019)
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
- Lisanne F. van Dessel,
- Job van Riet,
- Minke Smits,
- Yanyun Zhu,
- Paul Hamberg,
- Michiel S. van der Heijden,
- Andries M. Bergman,
- Inge M. van Oort,
- Ronald de Wit,
- Emile E. Voest,
- Neeltje Steeghs,
- Takafumi N. Yamaguchi,
- Julie Livingstone,
- Paul C. Boutros,
- John W. M. Martens,
- Stefan Sleijfer,
- Edwin Cuppen,
- Wilbert Zwart,
- Harmen J. G. van de Werken,
- Niven Mehra,
- Martijn P. Lolkema
Affiliations
- Lisanne F. van Dessel
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
- Job van Riet
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
- Minke Smits
- Department of Medical Oncology, Radboud University Nijmegen Medical Center
- Yanyun Zhu
- Division on Oncogenomics, The Netherlands Cancer Institute
- Paul Hamberg
- Department of Internal Medicine, Franciscus Gasthuis & Vlietland
- Michiel S. van der Heijden
- Center for Personalized Cancer Treatment
- Andries M. Bergman
- Division on Oncogenomics, The Netherlands Cancer Institute
- Inge M. van Oort
- Department of Urology, Radboud University Nijmegen Medical Center
- Ronald de Wit
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
- Emile E. Voest
- Oncode Institute
- Neeltje Steeghs
- Center for Personalized Cancer Treatment
- Takafumi N. Yamaguchi
- Informatics and Biocomputing Program, Ontario Institute for Cancer Research
- Julie Livingstone
- Informatics and Biocomputing Program, Ontario Institute for Cancer Research
- Paul C. Boutros
- Informatics and Biocomputing Program, Ontario Institute for Cancer Research
- John W. M. Martens
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
- Stefan Sleijfer
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
- Edwin Cuppen
- Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht
- Wilbert Zwart
- Division on Oncogenomics, The Netherlands Cancer Institute
- Harmen J. G. van de Werken
- Cancer Computational Biology Center, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
- Niven Mehra
- Department of Medical Oncology, Radboud University Nijmegen Medical Center
- Martijn P. Lolkema
- Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam
- DOI
- https://doi.org/10.1038/s41467-019-13084-7
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Detecting genomic abnormalities in metastatic castration-resistant prostate cancer (mCRPC) may impact clinical treatment. Here, the authors present whole-genome sequencing of metastatic biopsies from 197 mCRPC patients, highlighting the landscape of microsatellite stability, homologous repair deficiency, and other genomic subgroups.
